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Nonalcoholic fatty liver disease (NAFLD) is a common chronic liver disease that ranges in severity from simple steatosis to
cirrhosis. NAFLD is considered to be associated with hepatic metabolic disorders, resulting in overaccumulation of fatty
acids/triglycerides and cholesterol. The pathogenesis and progression of NAFLD are generally explained by the “two-hit theory.”
Most studies of lipid metabolism in the NAFLD liver have focused on the metabolism of fatty acids/triglycerides; therefore, the
impact of cholesterol metabolism is still ambiguous. In this paper, we review recent studies on NAFLD from the viewpoint of
hepaticlipidmetabolism-associatedfactorsanddiscusstheimpactofdisorderedcholesterolmetabolismintheetiologyofNAFLD.
The clinical signiﬁcance of managing cholesterol metabolism, an option for the treatment of NAFLD, is also discussed.
1.Introduction
Histological features of nonalcoholic fatty liver disease
(NAFLD) include steatosis, hepatocellular ballooning, the
formationofMallorybodies,apoptosis/necrosis,andinﬂam-
mation [1]. Around 10–20% of patients with NAFLD have
nonalcoholic steatohepatitis (NASH), which can develop
into cirrhosis and hepatocellular carcinoma [2–5]. Because
excess nutrition intake is one of the main causes, NAFLD is
often accompanied by obesity, insulin resistance, hyperten-
sion, and/or dyslipidemia, which are manifestations of the
metabolicsyndrome[6].Therefore,nutritionalmanagement
and therapeutic exercise are fundamental steps to treat
NAFLD.
The “two-hit theory” is increasingly being adopted to
explain the pathogenesis of NAFLD and NASH [7]. In this
theory, the ﬁrst hit consists of the accumulation of fatty
acids/triglycerides in the liver, while the second hit involves
oxidative stress, mitochondrial dysfunction, and inﬂamma-
tion, which ultimately cause liver damage. It is also clear that
inﬂammatory cytokines and insulin resistance are closely
associated with fatty liver during the progression of NAFLD.
In previous studies that examined lipid metabolism in the
context of NAFLD, dysregulation of cholesterol metabolism
has received much less attention than have fatty acids and
triglycerides.Inthispaper,wefocusontheroleofcholesterol
and its metabolites on the pathogenesis of NAFLD, and
also the validity of cholesterol management as a method of
treating this disease.
2.FattyAcidMetabolisminthe NAFLD Liver
Hepatic lipid homeostasis represents a balance between
lipid uptake, synthesis, catabolism, and secretion. Therefore,
steatosis, a typical characteristic of NAFLD, is expected to be
caused by disordered lipid metabolism, particularly inhibi-
tion of fatty acid oxidation and enhanced lipogenesis. Many
factors involved in hepatic lipid metabolism pathways have
beenidentiﬁed,eventhoughtheprecisecellularnetworksare
not fully elucidated.
Adiponectin regulates hepatic fatty acid uptake and de
novo lipogenesis. AMP-activated protein kinase (AMPK)
works as a metabolic master switch, and its activity is reg-
ulated by adiponectin and tumor necrosis factor-α (TNFα).2 International Journal of Hepatology
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Figure 1: Expression proﬁle of lipid metabolism-associated factors in nonalcoholic fatty liver disease (NAFLD). The established pathophys-
iological pathways in NAFLD involve increased delivery of fatty acids to the liver and increased SREBP-1c signaling because of cholesterol
overload and insulin resistance. ABCG5/G8: ATP-binding cassette G5/G8; ACC: acetyl-CoA carboxylase; AdipoR: adiponectin receptor;
ADRP: adipose diﬀerentiation-related protein; AMPK: AMP-activated protein kinase; ApoB: apolipoprotein B; CM: chylomicron; CPT-
1: carnitine palmitoyltransferase-1; DGAT1: diacylglycerol acyltransferase 1; FAS: fatty acid synthase; HMGR: HMG-CoA reductase; HSL:
hormone sensitive lipase; IR: insulin receptor; IRS2: insulin receptor substrate 2; LDLR: LDL receptor; LXRα:l i v e rXr e c e p t o rα; MTP:
microsomal triglyceride transfer protein; NPC1L1: Niemann-Pick C1-like 1; PPARα: peroxisome proliferator-activated receptor α;S R E B P :
sterol regulatory element-binding protein; TNFα: tumor necrosis factor α; TNFR: TNF receptor.
Inhibition of AMPK results in the activation of sterol regula-
toryelement-bindingprotein-1c(SREBP-1c),whichupregu-
lates fatty acid synthesis-associated enzymes, such as acetyl-
CoA carboxylase (ACC) and fatty acid synthase (FAS). This
leads to enhanced fatty acid synthesis and overproduction of
triglycerides, ultimately resulting in liver steatosis [8]. Fatty
acids are used for β-oxidation in mitochondria and per-
oxisomes under the regulation of peroxisome proliferator-
activated receptor-α (PPARα). Fatty acids are ligands for
PPARα,whichtransactivatestheexpressionofgenesinvolved
in the transport, oxidation, and export of free fatty acids,
includingcarnitinepalmitoyltransferase-1(CPT-1),therate-
limiting enzyme in fatty acid β-oxidation.
The relationship between NAFLD and lipid metabolism
has been extensively investigated in studies that analyzed
the hepatic gene expression proﬁle in animals fed a high-fat
diet [9] and in liver biopsy samples from NAFLD patients
[10–14], and their expression proﬁles have been compared
with those in normal individuals. Figure 1 summarizes the
pathological changes in the NAFLD liver, which may lead to
theaccumulationoftriglycerides,freefattyacids,andcholes-
terol. To our knowledge, the following events are known to
occur in NAFLD. First, hepatic steatosis develops because
of upregulated fatty acid synthesis, but it is questionable
whether downregulation of fatty acid oxidation is also in-
volved [15–18]. Second, adiponectin production is reduced
because of increased visceral fat accumulation. Adiponectin
levels are inversely proportional to insulin resistance and
hepaticsteatosisinNAFLDpatients[19].Third,insulinresis-
tance, which is common in NAFLD, causes fatty liver, while
increasesinhepatocytefattyacidslevelscausehepaticinsulin
resistance [20]. Fourth, the severity of insulin resistance is
correlatedwiththeseverityofNASH.Fifth,disturbedinsulin
signaling in hepatocytes leads to steatosis associated with
the activation of SREBP-1c and the induction of fatty acid
synthesis [21].
Recent ﬁndings suggest that the cannabinoid system is
also involved in the development of fatty liver [22–24]. In
animal studies, cannabinoid 1 (CB1) receptors were acti-
vated by a high-fat diet via induction of the synthesis of
endocannabinoids, such as 2-arachidonoylglycerol and an-
andamide. CB1 receptor activation enhanced the expression
of several lipogenic factors, including SREBP-1c, ACC and
FAS, and downregulated CPT-1, resulting in increased de
novo fatty acid synthesis and suppression of fatty acid oxi-
dation. However, in the context of lipid metabolism, the
signaling pathway downstream of the cannabinoid receptor
has not been identiﬁed.
3.Cholesterol MetabolisminNAFLD
In humans, cholesterol is absorbed from the diet and synthe-
sizedbycellsinvarioustissues.Ahealthymanweighing60kg
contains approximately 140g of cholesterol, but only 1% ofInternational Journal of Hepatology 3
the total cholesterol is involved in a dynamic metabolic cycle
[25]. In one study, the mean intake of dietary cholesterol
wasestimatedtobe300–500mg/day[14].Theyalsoreported
that the dietary cholesterol aggregates into micelles with
biliary cholesterol (800–1300mg/day) in the duodenum
[14]. Physiologically, approximately 50% of the cholesterol
is absorbed in the jejunum via a cholesterol transporter
Niemann-Pick C1-like 1 (NPC1L1) expressed on the brush
border membrane. The cholesterol is then transported to
the liver in the form of chylomicrons and chylomicron
remnants [26]. NPC1L1, which may facilitate the hepatic
accumulation of cholesterol, is expressed on the canalicular
membrane of hepatocytes in humans. Another transporter
pump system involving ATP-binding cassette (ABC) G5/G8
excretes cholesterol into bile [27].
The main metabolic pathways of cholesterol in hepato-
cytes include (1) cholesterol de novo synthesis (acetyl-CoA-
mevalonate-cholesterol pathway); (2) cholesterol uptake in
the form of LDL and chylomicron remnants; (3) cholesterol
excretion into the blood in the form of VLDL; (4) cholesterol
excretion and uptake through bile via ABCG5/G8 and
NPC1L1, respectively; (5) synthesis of bile acids and their
excretion. Under normal conditions, these pathways interact
with each other to maintain cholesterol levels within a spe-
cific range.
However, in NAFLD patients, these systems are highly
disorganized. SREBPs act as regulators of hepatic cholesterol
levels and activate genes involved in the synthesis of choles-
terol and free fatty acids [28]. SREBP cleavage-activating
protein (SCAP) has a cholesterol-sensing domain that senses
intracellular cholesterol levels and directs the activity of
SREBPs. Physiologically, when intracellular cholesterol levels
are low, SREBPs are ﬁrst translocated to the Golgi apparatus
by SCAP and undergo proteolytic cleavage. Next, the cleaved
activated form of SREBP is released to the nucleus. When
intracellular cholesterol levels are high, SCAP activity and
SREBP activation are suppressed. However, in the context
of NAFLD, the regulatory loop of SREBP is disturbed, even
if the intracellular levels of cholesterol and/or fatty acids
are high [29]. In our study using liver biopsy samples from
NAFLD patients, despite excess cholesterol accumulation in
hepatocytes, de novo cholesterol synthesis remained greatly
enhanced even though SREBP-2 expression was downreg-
ulated [30]. In the liver of these patients, as evidence of
e x c e s sc h o l e s t e r o la c c u m u l a t i o n ,c h o l e s t e r o lu p t a k ew a sr e -
ported to be suppressed because of markedly downregulated
expression of LDL receptor (LDLR). Cholesterol excretion
was enhanced viaoverexpression of ABCG5/G8, apolipopro-
tein B, and microsomal triglyceride transfer protein (MTP)
[30], but it was considered that the secretion of cholesterol
reaches a plateau in NAFLD patients. Even in this situation,
cholesterol synthesis continued with upregulated expression
of HMG-CoA reductase and synthase, farnesyl P-P synthase
and squalene synthase [30–32]. This is because excess levels
of cholesterol and its oxysterol metabolites, which are ago-
nists for liver X receptor-α (LXRα)[ 32], cause excess fatty
acidsynthesisandsteatosisbyactivatingtheLXRα-SREBP-1c
pathway.LXRαexpressionwasalsoupregulatedintheliverof
NAFLD patients [31, 32]. As shown in Figure 1, cholesterol
uptake in the form of LDL is limited by the intracellular
accumulation of fatty acid and cholesterol, while fatty acid
andcholesterolsynthesisareupregulatedintheNAFLDliver.
These ﬁndings suggest that the feedback system regulating
intracellular lipids levels is disrupted in NAFLD.
4. NutritionalAnalysisinNAFLD Patients
In some nutritional investigations, it has been suggested that
high-fat, high-fat plus low-protein, high-carbohydrate,
and/or high-cholesterol diets are the main causes of NAFLD
[33–36]. Although many NAFLD patients show excess nutri-
tion intake, obese, and/or insulin resistance, not all patients
exhibit these features. In our nutritional analysis on Japanese
population, nonobese NAFLD patients had some features
that diﬀered from those of obese patients [37]. Naturally,
the dietary intake levels of total energy, fat, and carbohydrate
were markedly higher in obese NAFLD patients with insulin
resistance than those in nonobese NAFLD patients and
healthy volunteers. The most interesting ﬁnding was that
cholesterol intake was signiﬁcantly higher in nonobese
NAFLD patients than in obese NAFLD patients although
cholesterol intake in obese patients was also signiﬁcantly
higher than that in healthy volunteers. In our hepatic ex-
pression analysis of lipid metabolism-associated genes, we
found that LXRα expression levels were signiﬁcantly higher
in nonobese NAFLD patients than in obese NAFLD patients
[13]. Of note, cholesterol overload can upregulate LXRα
expression and activate fatty acid synthesis by increasing
oxysterollevels,metabolitesofcholesterolthatactasagonists
for LXRα and activate the LXRα-SREBP-1c pathway. These
nutrition and gene expression proﬁles indicate that excess
cholesterol intake (i.e., cholesterol supply) itself can be a
strong stimulant for the development of steatosis, even
though the total calorie intake may be within the normal
range. Recent reports using model animals support our
ﬁndings in nonobese NAFLD patients. Fatty liver without
obesity can be established in animal models by feeding
them with a hypercholesterolemic diet containing normal
calorie level [38–40]. Although this animal model showed
marked hypercholesterolemia, which was not observed in
our patients, this may be because the diet for animals con-
tains a very high cholesterol content (0.2–1.25%). Moreover,
serumcholesterollevelsmaybepreservedinNAFLDpatients
because dietary cholesterol is promptly taken up into the
hepatocyte cholesterol pool.
5. Prospects for Cholesterol
Management Therapy
As described above, it seems that cholesterol overload ini-
tiates the development of NAFLD. The progression from
simple steatosis to steatohepatitis (NASH) usually involves
the second hit, such as oxidative stress and inﬂammation.
In some studies of nutritional animal models, the accu-
mulation of cholesterol rather than fatty acids/triglycerides
plays a critical role in this progression, possibly because of
increased susceptibility to oxidative cell death [41]. It has4 International Journal of Hepatology
also been suggested that the regulation of cholesterol can
control C-reactive protein levels and insulin sensitivity [41].
Conversely, in some reports, the progression of triglyceride
accumulation and suppression of fatty acid oxidation were
not hepatotoxic and actually protected against worsening
liver damage [42]. Therefore, cholesterol management may
be a promising treatment target for NAFLD.
Ezetimibe, a blood cholesterol lowering agent, is a
NPC1L1-speciﬁc inhibitor and selectively blocks 54% of
cholesterol absorption from the intestine in humans and in
animals [43, 44]. Ezetimibe is quickly absorbed, enters the
enterohepatic circulation, and has a half-life of 24 hours.
From a nutritional point of view, it is important that ezetim-
ibedoesnotinhibittheabsorptionoffat-solublevitamins.In
our clinical study, nonobese NAFLD patients showing excess
intake of dietary cholesterol were treated with ezetimibe
[45]. After starting the therapy, although signiﬁcant changes
were not seen in their body weight, their serum ALT levels
decreased by 49.3 ± 16.1% and 45.3 ± 24.2% at 6 and
12 months, respectively. Moreover, steatotic ﬁndings on
ultrasonography improved in some patients. Interestingly,
NPC1L1 knockout mice with excess nutrition intake were
resistant to fatty liver, while ezetimibe elicits therapeutically
signiﬁcant eﬀects in animal models of NAFLD [46, 47].
These ﬁndings demonstrate that over intake and hepatic
accumulation of cholesterol, leading to the activation of
the LXRα-SREBP-1c pathway, are closely related to the
development of NAFLD. Accordingly, inhibiting cholesterol
absorption or reducing dietary cholesterol intake may oﬀer
a reliable therapeutic strategy for NAFLD. It has also
been reported that HMG-CoA reductase inhibitors (statins)
improve serum ALT levels in NAFLD patient [48–50].
Considering these ﬁndings, reducing hepatocytic accu-
mulation of cholesterol may represent a fundamental treat-
mentstrategyforNAFLD[51].Toestablishtreatmentsfocus-
ing on cholesterol management, more clinical evidence is
clearly needed. For example, cholesterol-restricted diet or
lipid modulators (ezetimibe and statins) may be less eﬀective
in obese NAFLD patients with insulin resistance than in
nonobese patients. This is because other factors associated
with obesity and insulin resistance are involved in the
development of fatty liver, and these factors may mask the
eﬀect of ezetimibe. There are other questions that also need
to be answered. For example, does the therapeutic eﬀect
of statin in combination with ezetimibe surpass that of
monotherapy? Can long-term cholesterol management with
ezetimibe and/or statins really improve steatosis as well as
ALT levels in NAFLD? It is also important to assess whether
theclinicaleﬀectsofcholesterolmanagementareobservedin
patients with steatohepatitis (i.e., NASH) as well as patients
with simple steatosis, and whether there is a synergis-
tic/additiveeﬀectofcholesterolmanagementincombination
with antioxidant therapy or liver protection therapy.
6. Conclusions
The feedback system controlling intracellular lipids levels
is greatly disrupted in NAFLD. Lifestyle modiﬁcations oﬀer
simple therapeutic targets for NAFLD. Cognitive nutritional
support, which is aimed at reducing calorie-intake and
avoiding overeating, should be developed alongside phar-
maceutical treatments to prevent the disease progression to
cirrhosis and HCC. Excess cholesterol intake, in particular,
is a major stimulant for the development of fatty liver. The
accumulation of cholesterol rather than triglycerides may
play a critical role in the progression from simple steatosis to
steatohepatitis. Accordingly, strategies targeting cholesterol
accumulation oﬀer basic therapeutic approaches for NAFLD
patients, and cholesterol management therapy seems to
represent a promising treatment for NAFLD. The potential
clinical beneﬁt of cholesterol management for treating
NAFLD with respect to hepatic steatosis and injury should
be estimated in appropriately designed trials.
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